Electrotherapy medical device maker Zynex has received US Food and Drug Administration (FDA) clearance for its NexWave device.
The NexWave device is capable of delivering three modalities of stimulation: transcutaneous electrical nerve stimulation, interferential electrical stimulation and neuromuscular electrical stimulation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataZynex CEO Thomas Sandgaard said that the combined modalities of the company’s NexWave provide doctors and clinicians a comprehensive pain therapy solution for their patients.
”We believe this new product is unique in the electrotherapy industry and provides our sales force with a competitive edge to fuel revenue generation in our already rapidly growing Zynex Medical subsidiary," Sandgaard added.